147P Inductive Anti-Pd-1 and Albumin Paclitaxel/cisplatin on Pathological Response in Patients with Locally Advanced Oral Squamous Cell Carcinoma: A Single Arm Trial
L-P. Zhong,Y-Y. Huang,J-J. Sun,J. Li,M-J. Dong,G-P. Zhu,Q. Zhu
DOI: https://doi.org/10.1016/j.annonc.2021.10.166
IF: 51.769
2021-01-01
Annals of Oncology
Abstract:BackgroundIn patients with locally advanced and resectable oral squamous cell carcinoma (OSCC), major pathological response (MPR) to induction therapy (IT) may translate into improved survival, and it is important to explore better IT protocol for OSCC. The combination of anti-PD-1 and chemotherapy as inductive protocol has not been well issued in OSCC.MethodsThe prospective single arm trial (NCT04473716) was performed to evaluate the IT of anti-PD-1 (Toripalimab) and chemotherapy (albumin paclitaxel/cisplatin) in OSCC patients at clinical stage Ⅲ and ⅣA (AJCC 2018). The patients received two cycles (21 days each) of intravenous albumin paclitaxel (260mg/m2), cisplatin (75mg/m2) and Toripalimab (240mg) on day 1 and day 22. Radical surgery was performed within two weeks after IT. Post-operative radiotherapy or chemoradiotherapy was performed within 1.5 months after surgery. The primary endpoints of this trial were MPR and safety. The second endpoints were the rates of 2-year survival, local recurrence and adverse events (AEs). Primary tumors were assessed for the percentage of residual viable tumor cells on HE staining, and tumor with no more than 10% viable tumor cell was considered as MPR. This study has been approved by institutional ethics committee at Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine.ResultsFrom Nov. 2020 to Apr. 2021, 20 patients were enrolled, including 16 males and 4 females. They aged between 19 to 75 years, with a median of 54 years. The primary tumor site was 8 tongue, 6 mouth floor, 5 gingiva and 1 cheek, at clinical stage III (18) and IVA (2). The IT-related grade 3-4 AEs included one grade 4 neutropenia, one grade 3 hypokalemia, and one grade 3 rash. They were relieved after expectant treatment, and the subsequent standard treatment were unaffected. The MPR rate was 60% (12/20), including 30% (6/20) pCR (pathological complete response). According to RECIST 1.1, radiological evaluation on IT showed 2 CR, 10 PR, 7 SD and 1 PD.ConclusionsInductive Toripalimab and albumin paclitaxel/cisplatin in OSCC patients is safe and well-tolerated, with high MPR rate. This inductive protocol has a good prospect for clinical application in OSCC.Clinical trial identificationNCT04473716.Legal entity responsible for the studyL-P. Zhong.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. BackgroundIn patients with locally advanced and resectable oral squamous cell carcinoma (OSCC), major pathological response (MPR) to induction therapy (IT) may translate into improved survival, and it is important to explore better IT protocol for OSCC. The combination of anti-PD-1 and chemotherapy as inductive protocol has not been well issued in OSCC. In patients with locally advanced and resectable oral squamous cell carcinoma (OSCC), major pathological response (MPR) to induction therapy (IT) may translate into improved survival, and it is important to explore better IT protocol for OSCC. The combination of anti-PD-1 and chemotherapy as inductive protocol has not been well issued in OSCC. MethodsThe prospective single arm trial (NCT04473716) was performed to evaluate the IT of anti-PD-1 (Toripalimab) and chemotherapy (albumin paclitaxel/cisplatin) in OSCC patients at clinical stage Ⅲ and ⅣA (AJCC 2018). The patients received two cycles (21 days each) of intravenous albumin paclitaxel (260mg/m2), cisplatin (75mg/m2) and Toripalimab (240mg) on day 1 and day 22. Radical surgery was performed within two weeks after IT. Post-operative radiotherapy or chemoradiotherapy was performed within 1.5 months after surgery. The primary endpoints of this trial were MPR and safety. The second endpoints were the rates of 2-year survival, local recurrence and adverse events (AEs). Primary tumors were assessed for the percentage of residual viable tumor cells on HE staining, and tumor with no more than 10% viable tumor cell was considered as MPR. This study has been approved by institutional ethics committee at Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. The prospective single arm trial (NCT04473716) was performed to evaluate the IT of anti-PD-1 (Toripalimab) and chemotherapy (albumin paclitaxel/cisplatin) in OSCC patients at clinical stage Ⅲ and ⅣA (AJCC 2018). The patients received two cycles (21 days each) of intravenous albumin paclitaxel (260mg/m2), cisplatin (75mg/m2) and Toripalimab (240mg) on day 1 and day 22. Radical surgery was performed within two weeks after IT. Post-operative radiotherapy or chemoradiotherapy was performed within 1.5 months after surgery. The primary endpoints of this trial were MPR and safety. The second endpoints were the rates of 2-year survival, local recurrence and adverse events (AEs). Primary tumors were assessed for the percentage of residual viable tumor cells on HE staining, and tumor with no more than 10% viable tumor cell was considered as MPR. This study has been approved by institutional ethics committee at Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. ResultsFrom Nov. 2020 to Apr. 2021, 20 patients were enrolled, including 16 males and 4 females. They aged between 19 to 75 years, with a median of 54 years. The primary tumor site was 8 tongue, 6 mouth floor, 5 gingiva and 1 cheek, at clinical stage III (18) and IVA (2). The IT-related grade 3-4 AEs included one grade 4 neutropenia, one grade 3 hypokalemia, and one grade 3 rash. They were relieved after expectant treatment, and the subsequent standard treatment were unaffected. The MPR rate was 60% (12/20), including 30% (6/20) pCR (pathological complete response). According to RECIST 1.1, radiological evaluation on IT showed 2 CR, 10 PR, 7 SD and 1 PD. From Nov. 2020 to Apr. 2021, 20 patients were enrolled, including 16 males and 4 females. They aged between 19 to 75 years, with a median of 54 years. The primary tumor site was 8 tongue, 6 mouth floor, 5 gingiva and 1 cheek, at clinical stage III (18) and IVA (2). The IT-related grade 3-4 AEs included one grade 4 neutropenia, one grade 3 hypokalemia, and one grade 3 rash. They were relieved after expectant treatment, and the subsequent standard treatment were unaffected. The MPR rate was 60% (12/20), including 30% (6/20) pCR (pathological complete response). According to RECIST 1.1, radiological evaluation on IT showed 2 CR, 10 PR, 7 SD and 1 PD. ConclusionsInductive Toripalimab and albumin paclitaxel/cisplatin in OSCC patients is safe and well-tolerated, with high MPR rate. This inductive protocol has a good prospect for clinical application in OSCC. Inductive Toripalimab and albumin paclitaxel/cisplatin in OSCC patients is safe and well-tolerated, with high MPR rate. This inductive protocol has a good prospect for clinical application in OSCC.